

«SPITZENMEDIZIN VERBESSERT DIE ZUKUNFT DER KINDER»  
FREITAG, 2. SEPTEMBER 2022



Inputreferat 3

**Prof. Dr. J. P. Bourquin**

Chefarzt, Onkologie, Universitäts-Kinderspital Zürich

After **Jean-Pierre Bourquin's** residency at Children's Hospital Zurich and his MD/PhD at the University of Zurich, he joined the fellowship program at Dana-Farber Cancer Institute and Children's Hospital (Harvard Medical School) in Boston, USA. In 2004, he returned to the **University Children's Hospital of Zurich** to lead the hematological malignancy program. Since 2020, he is a Full Professor at the Faculty of Medicine, Head of the division of Oncology, Hematology, Immunology, Stem Cell Transplant and Somatic Gene Therapy. Professor Bourquin has made many seminal contributions in the field of pediatric hematology-oncology, specifically in pediatric leukemia. His research focus is on mechanisms of drug resistance in childhood acute lymphoblastic leukemia, in particular new approaches to target transcriptional dependencies and development of functional precision medicine approaches. These have paved the way for international studies for this group of vulnerable patients.

He established a program for immunotherapy and individualized therapy of resistant leukemia in Zurich and is the national leader for pediatric leukemia in Switzerland, where he chairs all relevant clinical studies in several international leadership roles. His current flagship active translational research programs include an international Drug Response Profiling Registry serving international trials (INFORM, Hem-iSmart, IntReALL, AIOEP-BFM-ALL) and the INTerCePT Project as part of the LOOP Zurich (intercept evolution to overcome treatment resistance in childhood and adult blood cancer, led by Prof. Th. Zenz), a Clinical Research Priority Program of the University of Zurich, precision hematology/oncology and he is member of the Steering Committee for Hematologic Malignancies of the Innovative Treatment for Childhood Cancer (ITCC) Consortium.

Zurich is the largest clinical and research center for pediatric oncology in Switzerland. **Jean-Pierre Bourquin** authored **more than 182 publications with >6713 citations** in this field. He has recently been appointed to the board of directors of the European Hematology Association (EHA) and he also serves as a Chair of the Resistant Disease Committee of the International BFM Study Group that coordinates all relevant clinical projects for patients with relapsed and refractory ALL.